Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression.
Previously, we demonstrated that type I interferon (IFN-alpha/beta) or a combination of IFN-alpha/beta and type II IFN (IFN-gamma) delivered by a replication-defective human adenovirus 5 (Ad5) vector protected swine when challenged 1 day later with foot-and-mouth disease virus (FMDV). To gain a more comprehensive understanding of the mechanism of protection induced by IFNs, we inoculated groups of six swine with Ad5-vectors containing these genes, challenged 1 day later and euthanized 2 animals from each group prior to (1 day postinoculation [dpi]) and at 1 (2 dpi) and 6 days postchallenge (7 dpi). Blood, skin, and lymphoid tissues were examined for IFN-stimulated gene (ISG) induction and infiltration by innate immune cells. All IFN-inoculated animals had delayed and decreased clinical signs and viremia compared to the controls, and one animal in the IFN-alpha treated group did not develop disease. At 1 and 2 dpi the groups inoculated with the IFNs had increased numbers of dendritic cells and natural killer cells in the skin and lymph nodes, respectively, as well as increased levels of several ISGs compared to the controls. In particular, all tissues examined from IFN-treated groups had significant upregulation of the chemokine 10-kDa IFN-gamma-inducible protein 10, and preferential upregulation of 2',5'-oligoadenylate synthetase, Mx1, and indoleamine 2,3-dioxygenase. There was also upregulation of monocyte chemotactic protein 1 and macrophage inflammatory protein 3alpha in the skin. These data suggest that there is a complex interplay between IFN-induced immunomodulatory and antiviral activities in protection of swine against FMDV.
Diaz-San Segundo
Fayna
F
Plum Island Animal Disease Center, USDA, ARS, NAA, P.O. Box 848, Greenport, NY 11944, USA.
Moraes
Mauro P
MP
de Los Santos
Teresa
T
Dias
Camila C A
CC
Grubman
Marvin J
MJ
D000260:Adenoviruses, Human / Q000235:genetics; D000818:Animals; D016207:Cytokines / Q000096:biosynthesis; D005536:Foot-and-Mouth Disease / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D029544:Foot-and-Mouth Disease Virus / Q000276:immunology* / Q000472:pathogenicity*; D015870:Gene Expression; D005822:Genetic Vectors; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D018836:Inflammation Mediators / Q000378:metabolism; D007370:Interferon Type I / Q000235:genetics / Q000276:immunology*; D007371:Interferon-gamma / Q000235:genetics / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology / Q000473:pathology; D007801:Langerhans Cells / Q000276:immunology / Q000473:pathology; D008297:Male; D011994:Recombinant Proteins; D034421:Sus scrofa; D013552:Swine; D013553:Swine Diseases / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D014766:Viremia / Q000235:genetics / Q000276:immunology / Q000517:prevention & control
D016207:Cytokines; D018836:Inflammation Mediators; D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma